Cobra Biologics, a UK-based contract development and manufacturing organization, and Alan Dickson, Professor of Biotechnology at The University of Manchester in the UK, has formed a two-year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported via the FLexible Interchange Program Scheme from the Biotechnology and Biological Sciences Research Council, a member of Research Councils UK budgeting around £509 million on research and capital grants, and fellowships to support around 1600 scientists and 2000 research students in universities and institutes across the UK.<\p>

Financial terms and terms relating to intellectual property were nto disclosed. The partnership is focused on achieving greater predictability and certainty in process development and scale-up of the production of protein-based biopharmaceuticals in therapeutic areas, including cancer and inflammation.<\p>

Source: Cobra Biologics